Search

Displaying results 2611 - 2620 of 10000 in total
  1. Drug

    Alkaline Phosphatase

    go.drugbank.com/drugs/DB05768
    Investigational

    Alkaline Phosphatase (AP) is an oral treatment and has a very favorable side-effect profile. … AP only acts locally in the colon to reduce the continuous inflammation of the colon by endotoxin from Gram-negative bacteria and extracellular ATP in UC patients.

  2. Drug

    Sulfaphenazole

    go.drugbank.com/drugs/DB06729
    Approved

    Sulfaphenazole is a sulfonamide antibacterial.

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 CYP2C8 InhibitorsSynonyms: 3-(p-aminobenzenesulfonamido)-2-phenylpyrazole
  3. Drug

    Pegloticase

    go.drugbank.com/drugs/DB09208
    ApprovedInvestigational

    [A249980] The PEG group also gives pegloticase a lower potential to induce an immune response. … [L42425] Pegloticase has a similar activity to rasburicase, an enzyme that metabolizes uric acid to allantoin.

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Tocotrienol

    go.drugbank.com/drugs/DB12647
    Investigational

    Tocotrienol has been investigated for the treatment of Cholesterol Lowering.

    Mixtures: Protect Cardio AFCategories: Compounds used in a research, industrial, or household setting
  5. Drug

    Mefenamic acid

    go.drugbank.com/drugs/DB00784
    Approved

    A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  6. Drug

    Fuzapladib

    go.drugbank.com/drugs/DB19478
    Experimental

    Fuzapladib is a small molecule drug. The usage of the INN stem '-pladib' in the name indicates that Fuzapladib is a phospholipase A2​ inhibitor. … Fuzapladib has a monoisotopic molecular weight of 379.12 Da.

    Categories: Phospholipase A2 Inhibitors, Phospholipases A, antagonists & inhibitors
  7. Drug

    Temsirolimus

    go.drugbank.com/drugs/DB06287
    ApprovedInvestigational

    Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007. … Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: TORISEL 25 MG/ML IV INFUZYONLUK COZELTI ICEREN FLAKON, 1 ADET
  8. Drug

    Sulfate ion

    go.drugbank.com/drugs/DB14546
    Investigational

    Mixtures: VAMIN 14 IV AMINOASIT SOLÜSYONU, 500 ML
  9. Drug

    Acenocoumarol

    go.drugbank.com/drugs/DB01418
    ApprovedInvestigational

    Acenocoumarol is a coumarin derivative used as an anticoagulant. Coumarin derivatives inhibit the reduction of vitamin K by vitamin K reductase.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic IndexSynonyms: 3-(alpha-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin, 3-(alpha-(p-Nitrophenol)-beta-acetylethyl)-4-hydroxycoumarin
  10. Drug

    Chlormerodrin Hg-197

    go.drugbank.com/drugs/DB09406
    Approved

    Chlormerodrin Hg-197 is a radiolabelled form of chlormerodrin, an organomercury compound that was previously used as a diuretic. Its radiolabelled form was used as diagnostics in brain scans.